First revenues for Genomics but bottom line widens
This article was originally published in Clinica
Molecular diagnostics specialist Rosetta Genomics recorded its first revenues, after posting $705,000 of sales in the third quarter of 2008. The Rehovot, Israel-based company attributed the revenues to Parkway Clinical Laboratories, the microRNA-based tests business, which it purchased in June 2008 (see Clinica No 1312, p 17). However, these revenues were unable to prevent Rosetta from posting a wider net loss for the period. The firm’s bottom line widened to $3.0m compared to the loss of $2.2m it reported during the same period last year. Net loss was impacted by higher operating expenses.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals